The FDA has cleared LumosityRx to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type ADHD.

There is no scientific evidence base for routine use of multiple psychiatric drugs, particularly for children.

A new NHS service providing high-quality, accessible ADHD assessment and treatment for adults has been launched In Leeds.

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Lumos Labs has obtained a clearance from the FDA for its popular Lumosity brain training platform, greenlighting a version of it to be marketed as a prescription ...

Offering screening for neurodivergence to people detained by the police could help ensure access to appropriate support and fairer treatment in the criminal ...

Follow the latest news headlines from Australia's most trusted source. Read in-depth expert analysis and watch live coverage on ABC News.

The most comprehensive review to date of ADHD treatments has found that medication for children and adults, and cognitive behavioral therapy for adults, remain the most effective approaches, backed by ...

(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta as an add-on therapy with antidepressants for the treatment of major ...

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

What Is Caplyta, and Why Does It Matter? Caplyta (lumateperone) is a once-daily oral medicine now approved to be used with antidepressants to treat major depressive disorder (MDD) in adults. It ...